E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Hereditary angioedema (HAE) is a rare genetic condition, where the body has local swellings in various body parts including the hands, feet, face and airway, (throat). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019860 |
E.1.2 | Term | Hereditary angioedema |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the PK, tolerability, and safety of a single SC dose of icatibant in children and adolescents with HAE during an acute HAE attack.
|
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy of a single SC dose of icatibant in children and adolescents with HAE.
To evaluate levels of reproductive hormones after a single SC dose of icatibant in children
and adolescents with HAE.
To evaluate continued safety of icatibant in pubertal/postpubeertal children after repeat exposure.
To evaluate reproductive hormone levels in pubertal/postpubeertal children after repeat exposure.
To evaluate the efficacy of icatibant in pubertal/postpubeertal children after repeat exposure. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Two through 17 years of age, inclusive (ie, from the second birthday until the day prior to the eighteenth birthday) at the time of the subject’s first HAE attack treated with icatibant as part of this study.
2. Documented diagnosis of HAE Type I or II. Diagnosis must be C1-1NH deficiency (C1-1NH protein level below the lower limit of normal and/or functional level <50% of normal). Diagnosis may be on the basis of historic data or by diagnostic testing conducted at the time of screening. Inclusion will be permitted initially based on medical history only if a clear diagnosis has been made based on all of the following criteria
-Family history
-Characteristic attack manifestations/recurrent attacks
-Historical N1-1NH deficiency as demonstrated by immunologic or functional test results
-Exclusion of other forms of angioedema
-Subsequent confirmation of the diagnosis to be made on the basis of C1-1NH level of function (all subjects)
3. Informed consent (and subject assent as appropriate) signed by the subject’s parent(s) or legal guardian(s). |
|
E.4 | Principal exclusion criteria |
1. Diagnosis of angioedema other than HAE.
2. Participation in another clinical trial that involves use of any investigational product (drug of device) within 30 days prior to study enrollment or at any time during the study.
3. Any known factor/disease that might interfere with the treatment compliance, study conduct or result interpretation.
4. Congenital or acquired cardiac anomalies that interfere significantly with cardiac function.
5. Treatment with ACE inhibitors within 7 days prior to treatment.
6. Use of hormonal contraception within the 90 days prior to treatment.
7. Androgen use (eg, stanozolol, danazol, oxandrolone, methyltestosterone, testosterone) within the 90 days prior to treatment.
8. The subject is pregnant or breastfeeding.
9. A physical condition that interferes with pubertal status determination |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The PK profile of icatibant after a single SC injection in pediatric subjects treated for acute attacks of HAE.
The tolerability and safety of SC icatibant as assessed by injection site reactions, AEs, vital signs, ECG recordings, physical examination, clinical laboratory parameters (serum chemistry [including liver function tests], hematology, urinalysis), reproductive hormone levels, and immunogenicity (presence of anti-icatibant antibodies). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Post-Treatment Day 1 through Day 8 (±1 days)
Follow-up Day 9 through Day 90 (±7 days)
Two additional icatibant-treated attacks for a total of 3 icatibant-treated attacks
(Pubertal/postpubertal subjects only)
Treatment Day 1
Post-Treatment Day 1 through Day 8 (±1 days)
Follow-up Day 9 through Day 90 (±7 days) |
|
E.5.2 | Secondary end point(s) |
For all subjects (2 to 17 years of age): investigator assessment and scoring of cutaneous, abdominal, and laryngeal symptoms of acute HAE attacks by an investigator-rated symptom score.
- The time to onset of relief of symptoms, defined as the earliest time at which a 20% improvement is seen in the average post-treatment score with no worsening of any single component score.
- The time to minimal symptoms, defined as the earliest time post-treatment when all symptoms are either mild or absent based on the investigator-rated symptom score.
• For subjects ≥4 years of age only: subject self-assessment of HAE-related pain using the Faces Pain Scale-Revised (FPS-R). The time to onset of relief of symptoms, defined as the earliest time at which a 20% improvement is seen in the post-treatment score.
• For subjects <4 years of age only: investigator assessment of HAE-related pain using the Faces, Legs, Activity, Cry, and Consolability (FLACC) scale. The time to onset of relief of symptoms, defined as the earliest time at which a 20% improvement is seen in the total post-treatment score.
• The incidence of rescue medication use.
• The proportion of subjects with worsened intensity of clinical HAE symptoms between 2 and 4 hours after treatment with SC icatibant using investigator-rated symptom scores. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Post-Treatment Day 1 through Day 8 (±1 days)
Follow-up Day 9 through Day 90 (±7 days)
Two additional icatibant-treated attacks for a total of 3 icatibant-treated attacks
(Pubertal/postpubertal subjects only)
Treatment Day 1
Post-Treatment Day 1 through Day 8 (±1 days)
Follow-up Day 9 through Day 90 (±7 days) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Germany |
Hungary |
Israel |
Italy |
Spain |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Once the sixteenth prepubertal subject and the twentieth pubertal/postpubertal subject has completed the 6 month follow-up after treatment for an initial attack, and the fifteenth pubertal/postpubertal subject has completed the 6 month follow-up after the third and final treatment, the study will be closed.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 10 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |